Cutaneous lupus: recognising DLE, SCLE, and ACLE in general practice

Cutaneous lupus erythematosus (CLE) is an umbrella term for several autoimmune, photosensitive inflammatory skin conditions. It is substantially more common than systemic lupus erythematosus (SLE) — isolated skin-limited CLE is roughly three to four times more frequent than systemic disease. Yet CLE carries real implications for general practice: every new diagnosis requires a targeted workup to exclude SLE, photoprotection and hydroxychloroquine are the pillars of management, and smoking has a specific detrimental effect on treatment response that clinicians must address at every review.

The general practice role is to recognise the clinical subtypes, arrange a thorough initial workup, initiate or co-manage hydroxychloroquine, and identify the minority of patients who have concurrent SLE requiring urgent specialist care. EULAR 2023 management recommendations and Therapeutic Guidelines provide the current evidence base for day-to-day clinical decisions.

A. Core clinical — the Gilliam classification framework

CLE is classified using the Gilliam system into three main groups, each with different clinical features, SLE association, and management implications.

Acute cutaneous lupus (ACLE) is the malar or “butterfly” rash — photo-distributed erythema across both cheeks and the nasal bridge that spares the nasolabial folds (a key distinguishing feature from rosacea and seborrhoeic dermatitis). It occurs in approximately 50% of SLE patients and is strongly associated with systemic disease. It resolves without scarring, though it may leave post-inflammatory hyperpigmentation particularly in darker skin tones.

Subacute cutaneous lupus (SCLE) presents as annular polycyclic or papulosquamous plaques distributed across the V of the chest, upper back, shoulders, and extensor arms. It classically spares the face and below the waist. Anti-Ro/SSA antibodies are positive in approximately 75% of SCLE cases per the British Association of Dermatologists 2021 guidelines. Approximately half of SCLE patients have mild SLE; severe organ disease is uncommon. Drug-induced SCLE is a critical diagnostic consideration — commonly implicated agents include thiazide diuretics (especially HCTZ), ACE inhibitors, terbinafine, proton-pump inhibitors, statins, calcium-channel blockers, and TNF inhibitors. The rash typically appears four to twenty weeks after commencing the drug and usually resolves within months of withdrawal. Drug review is mandatory in every new SCLE presentation.

Chronic cutaneous lupus — discoid lupus erythematosus (DLE) is the most common CLE subtype. DLE causes persistent, indurated, coin-shaped plaques with follicular hyperkeratosis (the “carpet-tack” sign when scale is lifted), scarring, dyspigmentation, and irreversible atrophy. Sun-exposed areas of the face, scalp, and ears (conchal bowl) are most affected. Scalp involvement causes scarring cicatricial alopecia — hair loss that does not regrow once the follicle is destroyed. Localised DLE (head and neck only) carries approximately 5% risk of transitioning to SLE; generalised DLE (above and below the waist) carries up to 25% transition risk per eTG Dermatology.

Less common subtypes include lupus erythematosus tumidus (urticarial, non-scarring, highly photosensitive), lupus profundus or panniculitis (deep subcutaneous nodules causing lipoatrophy), and chilblain lupus (cold-triggered purple plaques on fingers, toes, and ears).

Neonatal lupus is a transplacental complication — maternal anti-Ro/SSA (± anti-La/SSB) antibodies cross the placenta and cause an annular photosensitive neonatal rash plus, critically, congenital heart block in a minority of infants. Cardiac conduction damage is irreversible and may require pacing. Mothers are sometimes entirely asymptomatic at the time of the infant’s diagnosis.

GP workup at new CLE diagnosis: every patient requires:

• Full blood count, ESR, CRP, UEC, LFT — note that low CRP with high ESR is a classic SLE fingerprint; elevated CRP in SLE should prompt consideration of infection or serositis rather than lupus flare
• ANA (sensitive ~95% for SLE), anti-dsDNA, anti-Sm, anti-Ro/SSA + anti-La/SSB, C3 and C4
• Antiphospholipid panel — lupus anticoagulant, anti-cardiolipin, anti-β2 glycoprotein 1
• Urine albumin-to-creatinine ratio and dipstick with microscopy for dysmorphic red cells (lupus nephritis)
• HbA1c, lipids, vitamin D, TFTs — baseline for corticosteroid treatment and CV risk

B. Evidence on management — hydroxychloroquine, photoprotection, and biologics

Hydroxychloroquine (HCQ) is first-line systemic therapy for all CLE/SLE per EULAR 2023 and eTG. It reduces flare frequency by approximately 50% and improves ten-year survival in SLE. The standard PBS-listed dose is 200–400 mg daily; the critical safety constraint is that the dose must not exceed 5 mg per kg of ideal body weight to minimise retinopathy risk. A dose of 400 mg per day is appropriate for patients weighing 80 kg or more by ideal body weight, but is excessive in smaller-framed patients.

HCQ retinopathy screening is mandatory: ophthalmology assessment (OCT, automated visual field, fundus autofluorescence) at baseline, then annually from year 5 of use, or earlier if the patient has chronic kidney disease, pre-existing retinal disease, or a dose above 5 mg/kg IBW per RANZCO 2018 guidelines.

Smoking and HCQ resistance is a well-established clinical finding. A systematic review by Chasset et al., JAAD 2015 involving nearly 1,400 patients found that current smokers were approximately twice as likely to have inadequate response to hydroxychloroquine as non-smokers. Smoking cessation is therefore not merely a general health recommendation — it is a specific disease modifier in CLE.

Topical therapy: potent topical corticosteroids are effective for localised lesions away from the face. Topical tacrolimus 0.1% is an effective steroid-sparing option for facial lesions and sensitive-area disease, avoiding the atrophy associated with prolonged topical steroid use per AAD 2024 guidelines.

Step-up immunosuppression for refractory CLE/SLE:

• Methotrexate 7.5–25 mg weekly with folic acid
• Mycophenolate mofetil 1–3 g daily in divided doses
• Azathioprine 1–2.5 mg/kg/day (check TPMT levels before initiation)

Biologics for moderate-severe SLE:

• Belimumab (anti-BLyS, Benlysta): the BLISS-52 trial, BLISS-76, and BLISS-LN trials demonstrated consistent reduction in SLE disease activity, flare rate, and — for BLISS-LN — lupus nephritis progression. PBS Section 100 Authority listing for active SLE refractory to standard therapy — verify current eligibility criteria with the PBS
• Anifrolumab (anti-IFNAR1, Saphnelo): TGA registered 2022; TULIP-2 NEJM 2020 showed BICLA response significantly superior to placebo, with particularly strong skin disease response (CLASI-50 ~49% vs 25%). PBS authority criteria — verify current listing

Photoprotection: SPF 50+ broad-spectrum sunscreen applied daily (not just on sunny days), UPF 50+ clothing, broad-brimmed hat, and seeking shade during peak UV hours (10 am to 3 pm) is the most important non-pharmacological intervention for all CLE subtypes. UV light triggers every CLE subtype and can precipitate systemic SLE flares.

C. Long-term monitoring and SLE screening priorities

Patients on hydroxychloroquine require:

• Annual ophthalmology review from year 5 (as above)
• Repeat ANA, anti-dsDNA, C3/C4, UEC, and urine ACR at 6–12 monthly intervals in clinically stable patients — more frequently during flares or with new systemic symptoms
• Blood pressure at every visit (lupus nephritis and corticosteroid effects)
• Lipid profile and cardiovascular risk reassessment annually — SLE carries a two- to three-fold excess cardiovascular risk per EULAR 2023
• Bone density (DXA) with cumulative corticosteroid exposure; calcium and vitamin D supplementation
• Vaccination review — annual influenza, COVID-19, pneumococcal, dTpa; avoid live vaccines (MMR, varicella, yellow fever, BCG, oral typhoid) in immunosuppressed patients per the Australian Immunisation Handbook
• Pre-conception counselling for women of reproductive age — methotrexate and mycophenolate are teratogenic and must be ceased at least three months before conception; HCQ and azathioprine are compatible with pregnancy

D. Australian operations — MBS, PBS, and specialist referral

MBS items:

• Items 23 / 36 / 44 — Level B/C/D consultations for CLE assessment and multi-system review
• Items 965 / 967 — GPCCMP preparation and review (post-1-July-2025 single-plan framework); enables allied health referrals including mental health, dietitian, physiotherapy
• Items 2715 / 2717 — Mental Health Care Plan — depression and anxiety are prevalent in SLE (up to 30%)
• Items 65070, 66536, 66541 — FBC, general chemistry, HbA1c pathology bundles
• Item 71093 — Autoimmune serology (ANA, ENA, anti-dsDNA, complement, antiphospholipid panel — verify current bundled item coding)
• Item 73529 — Urine albumin-to-creatinine ratio
• Item 30071 / 30075 — Skin biopsy if diagnosis is uncertain (punch, shave, or excision)
• Item 11221 — Ophthalmology comprehensive assessment (HCQ baseline and annual screening)
• Item 715 — Aboriginal and Torres Strait Islander Health Assessment

PBS prescribing:

• Hydroxychloroquine — General Schedule for rheumatic disease; broadly accessible; 200 mg tablets
• Topical betamethasone, mometasone, methylprednisolone aceponate — General Schedule for inflammatory skin disease
• Topical tacrolimus 0.1% — PBS Authority for atopic dermatitis; off-label for CLE (patient cost if outside on-PBS indication)
• Methotrexate — PBS Authority Required (typically specialist initiation for SLE)
• Mycophenolate mofetil — PBS Authority Required for lupus nephritis
• Belimumab (Benlysta) — PBS Section 100 Highly Specialised Drugs, Authority Required
• Prednisolone — General Schedule; EULAR 2023 recommends targeting maintenance dose ≤5 mg daily

Referral pathways:

• Rheumatology — same-day for suspected severe SLE (nephritis, neuropsychiatric features, haematological crises, cardiopulmonary involvement); routine within weeks for any CLE with systemic features or meeting EULAR/ACR 2019 classification criteria
• Dermatology — refractory CLE, diagnostic uncertainty, hypertrophic DLE (exclude squamous cell carcinoma), scarring alopecia, lupus profundus
• Nephrology — same-day for proteinuria with active sediment or acute kidney injury
• Ophthalmology — HCQ baseline and annual screening from year 5
• Lupus Foundation Australia — peer support and patient education at lupus.org.au

E. Special populations

Skin of colour: DLE in patients with darker skin phototypes causes more pronounced dyspigmentation (central hypopigmentation and peripheral hyperpigmentation), which can be as psychologically distressing as the scarring itself. Cosmetic camouflage products and referral to a camouflage clinic carry significant quality-of-life benefit. Post-inflammatory pigment changes respond partially to time and topical treatment.

Adolescents and young adults: SLE has a peak onset between 15 and 45 years. Adolescent patients face additional challenges around treatment adherence, body image, fertility planning, and social participation. Mental health screening and MHCP referral should be offered proactively.

Pregnancy and conception: Anti-Ro/SSA and anti-La/SSB antibodies must be checked pre-conception — they carry risk of neonatal lupus and congenital heart block in the infant. Active lupus nephritis substantially increases obstetric risk. PROMISSE cohort data documents higher rates of preterm birth, pre-eclampsia, and fetal loss. HCQ and azathioprine are safe in pregnancy; methotrexate, mycophenolate, and cyclophosphamide are not.

Aboriginal and Torres Strait Islander populations: SLE is more prevalent and tends to be more severe in First Nations Australians, with higher rates of lupus nephritis and end-organ damage. Use of MBS item 715 (ATSI Health Assessment) facilitates comprehensive initial workup. Coordination with Aboriginal Community Controlled Health Organisations is important for culturally safe management.

Drug-induced SCLE recognition: Given the breadth of trigger medications (thiazides, ACEi, PPIs, statins, terbinafine, TNF inhibitors, checkpoint inhibitors), a complete medication review is essential at diagnosis. The temporal relationship — rash appearing four to twenty weeks after commencing a drug — is the strongest diagnostic clue.

When to escalate

Arrange same-day emergency assessment for:

• Lupus nephritis: proteinuria (urine ACR >30 mg/mmol), haematuria with dysmorphic red cells, or acute kidney injury in a known or suspected SLE patient
• Neuropsychiatric SLE: new seizures, psychosis, stroke, or acute cognitive change in a lupus patient
• Catastrophic antiphospholipid syndrome: multi-organ thrombosis with thrombocytopenia
• Severe haematological crisis: profound anaemia with haemolysis, or platelet count below 20 × 10⁹/L
• Active lupus with pregnancy: high-risk obstetric and rheumatology co-management required

Arrange urgent rheumatology review within one to two weeks for:

• New CLE with any systemic features (joint swelling, pleuritic pain, oral ulcers, unexplained fatigue, unexplained lymphadenopenia) even without meeting full EULAR/ACR criteria
• DLE with positive anti-dsDNA or low complement on initial workup

What this article is and is not

This article provides educational information about cutaneous lupus erythematosus for patients and clinicians, based on current guidelines including EULAR 2023, eTG, and the RACGP. It does not constitute personal medical advice and is not a substitute for assessment by a qualified healthcare professional.

Management decisions — including whether to start hydroxychloroquine, which dose is appropriate for an individual patient’s body weight, and when to escalate to specialist care — must be made by a treating clinician with full knowledge of the patient’s history and test results. Dr Hoe Bing Lo is an AHPRA-registered general practitioner (MED0001212640, FACRRM) practising in Australia. This article has not yet undergone specialist AHPRA review and is flagged accordingly.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Dermatology: Cutaneous lupus
2. Therapeutic Guidelines (eTG) — Rheumatology: Systemic lupus erythematosus
3. RACGP — Lupus: an overview for GPs
4. Australian Medicines Handbook (AMH) — hydroxychloroquine, belimumab, anifrolumab
5. EULAR/ACR 2019 SLE classification criteria — Aringer ARD 2019
6. EULAR 2023 SLE management recommendations — Fanouriakis ARD 2024
7. AAD — Cutaneous lupus management guideline 2024
8. British Association of Dermatologists — Guidelines for the management of cutaneous lupus 2021
9. RANZCO — Hydroxychloroquine retinopathy screening guideline 2018
10. Chasset et al. — Smoking and HCQ resistance in CLE. JAAD 2015
11. BLISS-52 — Navarra et al. Lancet 2011 (belimumab in SLE)
12. TULIP-2 — Morand et al. NEJM 2020 (anifrolumab in SLE)
13. Lupus Foundation Australia
14. HealthDirect — Lupus